{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Complete Responses"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Partial Responses"}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Efficacy as measured by objective response complete (CR) and partial (PR) response rates at 2 months following study treatment","groups":[{"description":"Oblimersen 3 mg/kg/day continuous intravenous infusion daily for 7 days on alternated weeks on week 1, 3 and 5 (days 1 through 7, 15 through 21, and 29 through 35); Rituximab 375 mg/m2 intravenous infusion for six doses on days 3, 8,15, 22, 29, and 36.","id":"OG000","title":"Oblimersen + Rituximab"}],"paramType":"NUMBER","populationDescription":"Analysis was per protocol. Of the 48 participants enrolled, only 42 were evaluable for response.","reportingStatus":"POSTED","timeFrame":"2 months following study treatment","title":"Number of Patients With Objective Response","type":"PRIMARY","unitOfMeasure":"participants"}